



(43) International Publication Date
18 September 2014 (18.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/145864 A1

(51) International Patent Classification:

D04H 1/74 (2006.01) **B29C 53/56** (2006.01)
D01D 5/06 (2006.01) **B29C 53/62** (2006.01)
A61F 2/02 (2006.01) **B29C 53/72** (2006.01)

(21) International Application Number:

PCT/US2014/030700

(22) International Filing Date:

17 March 2014 (17.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/798,265 15 March 2013 (15.03.2013) US

(71) Applicant: **NANOFIBER SOLUTIONS, LLC** [US/US];
1275 Kinnear Road, Columbus, Ohio 43212 (US).

(72) Inventor: **JOHNSON, Jed**; 1275 Kinnear Road, Colum-
bus, Ohio 43212 (US).

(74) Agents: **MILLER, Raymond A.** et al.; Suite 5000, 500
Grant Street, Pittsburgh, Pennsylvania 15219-2507 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: **BIOCOMPATIBLE FIBER TEXTILES FOR IMPLANTATION**

(57) Abstract: A biocompatible textile and methods for its use and fabrication are disclosed. The textile may be fabricated from electrospun fibers forming windings on a mandrel, in which the windings form openings having a mesh size between adjacent windings. The textile may also be fabricated by the addition of solvent-soluble particles incorporated into the textile while the windings are formed. Such particles may be removed by exposing the textile to a solvent, thereby dissolving them. Disclosed are also replacements for animal organs composed of material including at least one layer of an electrospun fiber textile having a mesh size. Such replacements for animal organs may include biocompatible textiles treated with a surface treatment process.



WO 2014/145864 A1

BIOCOMPATIBLE FIBER TEXTILES FOR IMPLANTATION

CLAIM OF PRIORITY

[0001] This applications claims benefit of and priority to U.S. Provisional Application No. 61/798,265 entitled "Biocompatible Fiber Textiles for Implantation" filed March 15, 2013, the disclosure of which is incorporated by reference herein in its entirety.

BACKGROUND

[0002] In order to repair or replace organs in patients, two independent and often mutually exclusive parameters must be met. First, any implant must have structural integrity including a certain amount of rigidity to remain in place once implanted. Second, an implant must be biocompatible so that it is not rejected by the body or create damaging inflammation. In certain instances the attachment, penetration, and proliferation of cells is also required for an implant to function as an organ as opposed to a simple prosthesis. No prior implant has been able to embody such parameters. For example, decellularized organ scaffolds, gels, and polymer matrices have been implanted, but one or more mechanical or biological issues have arisen. As such, none of these systems have been able to provide the appropriate mechanical properties along with the necessary bio-compatibility.

SUMMARY

[0003] In an embodiment, a biocompatible textile may include at least one electrospun fiber, composed of at least one polymer, that is disposed on a mandrel, in which the electrospun fiber forms a plurality of windings on the mandrel, each winding of the plurality of windings forming an opening with an adjacent winding, thereby forming a plurality of openings between a plurality of adjacent windings. The plurality of openings may compose a mesh size.

[0004] In an embodiment, a biocompatible textile may include an at least one electrospun fiber, composed of at least one polymer, that is disposed longitudinally along a linear axis of a mandrel, thereby forming a plurality of textile threads, in which the at least one electrospun fiber forms openings between adjacent linearly deposited textile threads of a mesh size. The plurality of openings may compose a mesh size.

[0005] In an embodiment, a method for fabricating a biocompatible textile may include electrospinning a biocompatible polymer into an electrospun fiber, contacting the electrospun fiber with a particulate material having a solubility in a solvent, contacting the electrospun fiber with a receiving surface, thereby forming a polymer network thereon composed of a plurality of electrospun fiber threads and a plurality of spaces between adjacent electrospun fiber threads, removing the polymer network from the receiving surface, thereby forming a biocompatible textile, and contacting the biocompatible textile with the solvent thereby removing the particulate material. The plurality of openings may compose a mesh size.

[0006] In an embodiment, a replacement for an animal organ may include a biocompatible textile composed of at least one electrospun fiber, comprising at least one polymer, disposed on a mandrel, in which the electrospun fiber forms a plurality of windings on the mandrel, each winding of the plurality of windings forming an opening with an adjacent winding, thereby forming a plurality of openings between a plurality of adjacent windings, and the plurality of openings comprises a mesh size. Additionally, the mandrel may have a shape of the animal organ or part thereof, and at least one surface of the biocompatible textile comprises windings of the at least one electrospun fiber treated with a surface treatment process.

BRIEF DESCRIPTION OF THE DRAWING

[0007] FIG. 1 illustrates an embodiment of a system for electrospinning a polymer fiber onto a mandrel in accordance with the present disclosure.

[0008] FIG. 2A illustrates an embodiment of a system for forming electrospun fibers as windings on a mandrel surface in accordance with the present disclosure.

[0009] FIG. 2B illustrates an embodiment of a system for forming electrospun fibers as threads along the longitudinal axis of a mandrel in accordance with the present disclosure.

[0010] FIGS. 3A and 3B depict a biocompatible textile formed without the addition of a water soluble material and a biocompatible textile formed with the addition of a water soluble material, respectively, in accordance with the present disclosure.

DETAILED DESCRIPTION

[0011] In some embodiments, a textile of embodiments herein may have a luminal structure composed of multiple windings of one or more biocompatible fibers. The term “textile” is defined herein as a spun, woven, or otherwise fabricated material comprising fibers. In some embodiments, the fibers may be wound about a mandrel as threads are wound around a bobbin. In some embodiments, the fibers may be deposited, in an essentially parallel manner, along a linear dimension of a mandrel or other surface form. In some embodiments, winding the textile may use electro-spinning techniques.

[0012] “Pore size” is thus defined herein as being the diameter of introduced pores, pockets, voids, holes, spaces, etc. introduced in an unmeshed structure such as block polymer, polymer sheet, or formed polymer scaffold and is specifically distinguished from “mesh size” as disclosed herein.

[0013] As used herein, the term “mesh size” is the number of openings in a textile per linear measure. For example, if the textile has 1200 openings per linear millimeter, the textile is defined 1200 mesh (e.g., sufficient to allow a 12 micron red blood cell to pass), which is easily convertible between imperial and metric units. A mesh size may be determined based on the number of fibers having a specified average diameter and an average opening size between adjacent fibers along a specified linear dimension. Thus, a textile composed of 10 μm average diameter fibers having 10 μm average diameter openings between adjacent fibers may have about 50 total openings along a 1 mm length and may therefore be defined as a 50 mesh textile.

[0014] As used herein, the term “implant” may refer to any structure that may be introduced for a permanent or semi-permanent period of time into a body. An implant may have the shape and size of a native organ or tissue that it may serve to replace. Alternatively, an implant may have a shape not related to a specific bodily organ or tissue. In yet another embodiment, an implant may have a shape of an entire bodily organ or tissue, or only a portion thereof. In still another example, an implant may be shaped like a portion of a bodily organ or tissue, or may simply comprise a patch of material. The implant may be designed for introduction into a body of an animal, including a human.

[0015] Disclosed herein are compositions and methods for use of textiles comprising spun fibers in biocompatible implants for patients. In certain embodiments, a polymer fiber is used such as polyurethane and/or polyethylene terephthalate. In some embodiments, a polymer fiber is spun over a mandrel so as to form a textile roll or tube. In some embodiments, the thickness of the textile roll or tube may be regulated by changing the number of rotations of the mandrel over time while the textile roll or tube collects the fiber. In certain other embodiments, the biocompatible textile has a mesh size of about 1 opening per mm to about 20 openings per mm. Some non-limiting examples of mesh sizes may include about 1 opening per mm, about 2 opening per mm, about 4 opening per mm, about 6 opening per mm, about 8 opening per mm, about 10 opening per mm, about 15 opening per mm, about 20 opening per mm, or ranges between any two of these values (including endpoints). In some embodiments, the mesh size of the spun textile may be about 20 openings per mm to about 500 openings per mm. Some non-limiting examples of mesh sizes may include about 20 openings per mm, about 40 openings per mm, about 60 openings per mm, about 80 openings per mm, about 100 openings per mm, about 200 openings per mm, about 300 openings per mm, about 400 openings per mm, about 500 openings per mm, or ranges between any two of these values (including endpoints). In other embodiments, the mesh size may be about 500 openings per mm to about 1000 openings per mm. Some non-limiting examples of mesh sizes may include about 500 openings per mm, about 600 openings per mm, about 700 openings per mm, about 800 openings per mm, about 1000 openings per mm, or ranges between any two of these values (including endpoints). In some embodiments, the mesh size of the textile may be regulated by changing the speed and direction by which the fiber is deposited onto the mandrel, such as by example moving the position and direction in which the thread is spun onto the textile roll or tube.

[0016] The textile having a mesh size may not only provide lightweight and flexible mechanical support, but also in certain embodiments, may allow cells to migrate into and throughout the mesh over time and may improve the biocompatibility of the implant. In yet other embodiments, the textile may provide sufficient structural rigidity so as to be surgically secured into an implant site while retaining sufficient flexibility under load stresses such as compression, shear, and torsion so as to allow the patient to physically move about once the implant is in place.

[0017] In yet other embodiments, the textile may include an additional surface treatment of the polymer fiber which can be used to modulate and enhance cellular attachment to the fibers. In yet other embodiments, the textile may not cause untreatable inflammation or rejection when implanted in a patient. As such, in certain embodiments, the textile implant may not be subject to rejection or life-threatening inflammation within 1 day, 3 days, 5 days, 7 days, 2 weeks, 3 weeks, a month or longer after implantation. In some embodiments, the textile implant can be retained in the patient for at least 1 day, 3 days, 5 days, 7 days, 2 weeks, 3 weeks, a month or longer. In certain embodiments, the implant may be retained in the patient for 6 months, a year, a term of years, or the lifetime of the patient. In some of the disclosed embodiments, spaces may be introduced through directional application of a polymer thread to a mandrel or other surface form during the electrospinning process as described herein. In some other embodiment, spaces may be introduced through the addition of particulates to the textile as the polymer fiber is deposited on a mandrel or other surface form during the electrospinning process as described herein.

[0018] While it is contemplated that any method or composition consistent with the disclosure is embodied, electrospun textiles may have specific advantages that are useful for implants. For example, when an electrospun textile is formed from a polymer network deposited on a mandrel, the traditional molding process can be bypassed since the polymer already exists in the form of a thread before the implant is shaped. As such, a textile based approach to creating biocompatible implants allows control of four critical parameters that cannot be controlled using inherently combined polymerization and molding processes. First, since the polymer is formed as a thread as part of the electrospinning process, there is no need for setting, curing or other time-consuming process. Second, the polymer fiber itself can be directed to any orientation for mesh spacing without resorting to chemical processes. The formation of a mesh obviates the need to create pores in an otherwise solid form. Third, the mesh size itself can be adjusted to be larger or smaller to promote ingrowth and proliferation of cells. Where such meshes are used to provide structural support for growing and migrating cells, the mesh may also operate as a cellular scaffold in addition to conferring the other advantages disclosed herein. In certain embodiments, a particle size can similarly be identified by the size of the mesh opening such as with the US sieve size, Tyler equivalent, mm, or inches. Fourth, the mesh can be sized to provide structural integrity such as rebound from deformation, and flexibility under load, and other advantageous mechanical properties.

Spinning textiles

[0019] The biocompatible textiles disclosed herein may be manufactured by any method. One non-limiting method may include break or open-end spinning, in which slivers are blown by air onto a rotating drum where they attach themselves to the tail of a formed textile (such as thread, rope or yarn) that is continually being drawn out from the drum. Other non-limiting methods may include ring spinning and mule spinning. In certain embodiments, a spinning machine may take a roving, thin it and twist it, thereby creating a yarn which may be wound onto a bobbin.

[0020] In mule spinning, the roving is pulled off a bobbin and fed through rollers, which feed at several different speeds, thinning the roving at a consistent rate. The thread, rope or yarn is twisted through the spinning of the bobbin as the carriage moves out, and is rolled onto a cop as the carriage returns. Mule spinning produces a finer thread than ring spinning. The mule process is an intermittent process, because the frame advances and returns a specific distance, which can produce a softer, less twisted thread favored for fines and for weft. The ring process is a continuous process, the yarn being coarser, and having a greater twist thereby being stronger and better suited to be warped. Similar methods have various improvements such as a flyer and bobbin and cap spinning.

Electrospinning textiles

[0021] Electrospinning is a method of spinning a polymer fiber or polymer nanofiber from a polymer solution by applying of a high voltage potential between the polymer solution (or polymer injection system containing the polymer solution) and a receiving surface for the electrospun polymer nanofibers. The voltage potential may include voltages less than or equal to about 30kV. The polymer may be ejected by a polymer injection system at a flow rate of less than or equal to about 50ml/h. As the polymer solution travels from the polymer injection system toward the receiving surface, it may be elongated into sub-micron diameter electrospun polymer nanofibers typically in the range of, about 0.1 μm to about 100 μm . Some non-limiting examples of electrospun polymer nanofiber diameters may include about 0.1 μm , about 0.2 μm , about 0.5 μm , about 1 μm , about 2 μm , about 5 μm , about 10 μm , about 20 μm , about 50 μm , about 100 μm , or ranges between any two of these values (including endpoints).

[0022] A polymer injection system may include any system configured to eject some amount of a polymer solution into an atmosphere to permit a flow of the polymer solution from the injection system to the receiving surface. In some non-limiting examples, the injection system may deliver a continuous stream of a polymer solution to be formed into a polymer nanofiber. In alternative examples, the injection system may be configured to deliver intermittent streams of a polymer to be formed into multiple polymer nanofibers. In one embodiment, the injection system may include a syringe under manual or automated control. In another embodiment, the injection system may include multiple syringes under individual or combined manual or automated control. In some examples, a multi-syringe injection system may include multiple syringes, each syringe containing the same polymer solution. In alternative examples, a multi-syringe injection system may include multiple syringes, each syringe containing a different polymer solution.

[0023] The receiving surface may move with respect to the polymer injection system or the polymer injection system may move with respect to the receiving surface. In some embodiments, the receiving surface may move with respect to the polymer injection system under manual control. In other embodiments, the surface may move with respect to the polymer system under automated control. In such embodiments, the receiving surface may be in contact with or mounted upon a support structure that may be moved using one or more motors or motion control systems. In some non-limiting examples, the surface may be a roughly cylindrical surface configured to rotate about a long axis of the surface. In some other non-limiting examples, the surface may be a flat surface that rotates about an axis approximately coaxial with the polymer fiber ejected by the polymer injection system. In yet some other non-limiting examples, the surface may be translated in one or more of a vertical direction and a horizontal direction with respect to the polymer nanofiber ejected by the polymer injection system. It may be further recognized that the receiving surface of the polymer nanofiber may move in any one direction or combination of directions with respect to the polymer nanofiber ejected by the polymer injection system. The pattern of the electrospun polymer nanofiber deposited on the receiving surface may depend upon the one or more motions of the receiving surface with respect to the polymer injection system. In one non-limiting example, a roughly cylindrical receiving surface, having a rotation rate about its long axis that is faster than a translation rate along a linear axis, may result in a roughly helical deposition of an electrospun polymer fiber forming windings about the receiving surface. In an alternative example, a receiving surface having a translation rate along a linear

axis that is faster than a rotation rate about a rotational axis, may result in a roughly linear deposition of an electrospun polymer fiber along a linear extent of the receiving surface.

[0024] In some embodiments, the receiving surface may be coated with a non-stick material, such as, for example, aluminum foil, a stainless steel coating, polytetrafluoroethylene, or combination thereof, before the application of the electrospun polymer nanofibers. The receiving surface, such as a mandrel, may be fabricated from aluminum, stainless steel, polytetrafluoroethylene, or combination thereof to provide a non-stick surface on which the electrospun nanofibers may be deposited. In other embodiments, the receiving surface may be coated with a simulated cartilage or other supportive tissue. In some non-limiting examples, the receiving surface may be composed of a planar surface, a circular surface, an irregular surface, and a roughly cylindrical surface. One embodiment of a roughly cylindrical surface may be a mandrel. A mandrel may take the form of a simple cylinder, or may have more complex geometries. In some non-limiting examples, the mandrel may take the form of a hollow bodily tissue or organ. Non-limiting embodiments of such bodily tissues may include a trachea, one or more bronchii, an esophagus, an intestine, a bowel, a ureter, a urethra, a blood vessel, or a nerve sheath (including the epineurium or perineurium).

[0025] The polymer solution may be a fluid composed of a solid polymer liquid by the application of heat. Alternatively, the polymer solution can comprise any polymer or combination of polymers dissolved in a solvent or combination of solvents. The concentration range of polymer or polymers in solvent or solvents may be, without limitation, about 5wt% to about 50wt%. Some non-limiting examples of polymer concentration in solution may include about 5 wt%, about 10 wt%, about 15 wt%, about 20 wt%, about 25 wt%, about 30 wt%, about 35 wt%, about 40 wt%, about 45 wt%, about 50 wt%, or ranges between any two of these values (including endpoints).

Polymers

[0026] In accordance with embodiments herein, a polymer solution used for electrospinning may typically include synthetic or semi-synthetic polymers such as, without limitation, a polyethylene terephthalate, a polyester, a polymethylmethacrylate, polyacrylonitrile, a silicone, a polyurethane, a polycarbonate, a polyether ketone ketone, a polyether ether ketone, a polyether imide, a polyamide, a polystyrene, a polyether sulfone, a

polysulfone, a polycaprolactone (PCL), a polylactic acid (PLA), a polyglycolic acid (PGA), a polyglycerol sebacic, a polydiol citrate, a polyhydroxy butyrate, a polyether amide, a polydioxanone, and combinations or derivatives thereof. Alternative polymer solutions used for electrospinning may include natural polymers such as fibronectin, collagen, gelatin, hyaluronic acid, chitosan, or combinations thereof. It may be understood that electrospinning solutions may also include a combination of synthetic polymers and naturally occurring polymers in any combination or compositional ratio. In some non-limiting examples, the polymer solution may comprise a weight percent ratio of polyethylene terephthalate to polyurethane of about 10% to about 75%. Non-limiting examples of such weight percent ratios may include 10%, 25%, 33%, 50%, 66%, 75%, or ranges between any two of these values.

[0027] The type of polymer in the polymer solution may determine the characteristics of the biocompatible textile. Some textiles may be composed of polymers that are bio-stable and not absorbable or biodegradable when implanted. Such textiles may remain generally chemically unchanged for the length of time in which they remain implanted. Alternative textiles may be composed of polymers that may be absorbed or bio-degraded over time. Such textiles may act as an initial template for the repair or replacement of organs and/or tissues. These organ or tissue templates may degrade *in situ* once the tissue or organs have been replaced or repaired by natural structures and cells. It may be further understood, that a biocompatible textile may be composed of more than one type of polymer, and that each polymer therein may have a specific characteristic, such as stability or biodegradability.

[0028] Polymer solutions may also include one or more solvents such as acetone, dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone, acetonitrile, hexanes, ether, dioxane, ethyl acetate, pyridine, toluene, xylene, tetrahydrofuran, trifluoroacetic acid, hexafluoroisopropanol, acetic acid, dimethylacetamide, chloroform, dichloromethane, water, alcohols, ionic compounds, or combinations thereof.

[0029] The polymer solutions may also include additional materials. Non-limiting examples of such additional materials may include radiation opaque materials, antibiotics, growth factors, vitamins, cytokines, steroids, anti-inflammatory drugs, small molecules, sugars, salts, peptides, proteins, cell factors, DNA, RNA, or any combination thereof.

Incorporation of an Anti-Static Bar

[0030] During electrospinning, polymer nanofibers are driven toward a receiving surface by charge separation caused by an applied voltage. The receiving surface typically is a conductive surface, composed of, for example, aluminum or copper. In some embodiments, the receiving surface is covered by a thin layer of plastic, ranging, for example, between about 0.001 inches (about 0.025 mm) to about 0.1 inches (about 2.5 mm) thick. The force that drives the electrospun polymer solution from the polymer injection system toward the receiving surface is derived from mobile ions within the polymer solution or melt. The polymer solution ejected by the polymer injection system may have a net positive or negative charge, depending upon the polarity of the voltage applied to the polymer injections system and the receiving surface. When the electrospun polymer nanofiber is deposited on the collector surface to form polymer nanofiber threads, a charge will build up as subsequent nanofiber thread layers are collected. It is believed that as the charge builds up on the receiving surface, the nanofibers threads, having a similar charge, will be repelled. This electrostatic repelling force may, thus, lead to irregularly arranged nanofiber threads that will have a lower degree of alignment. In order to reduce the effects of surface charge on the receiving surface or its polymer nanofiber threads, the use of an anti-static device, such as a bar, may be incorporated into the process to improve nanofiber thread alignment. The anti-static bar bombards the receiving surface with positively or negatively charged ions in the form of, for example, a plasma or corona discharge thereby neutralizing the charge on the receiving surface. Therefore, as fiber builds up over the receiving surface, successive layers of nanofiber threads will deposit more uniformly in a side-by-side arrangement (parallel relationship) to increase the alignment. In one embodiment, the position of an anti-static bar is parallel to the surface of the receiving surface, (for example, a roughly cylindrical mandrel, wheel, device, or plate) and may be, for example, about 0.5 inches (about 13 mm) to about 3 inches (about 75 mm) away from the receiving surface.

[0031] Experimental results demonstrated that nanofiber thread alignment on the receiving surface was improved significantly with the addition of an anti-static bar, when compared to samples spun under the same conditions without the anti-static bar. For example, the alignment of nanofiber threads can be about 83% at a low angle orientation when deposited on a receiving surface lacking an anti-static bar. However, a 12% increase in fiber alignment – to about 95% – may be observed with the use of an anti-static bar. The use of an

anti-static bar may also lead to improvements in nanofiber thread alignment on the receiving surface for processes incorporating polymer injection systems having multiple syringes. When nanofiber threads are deposited on a receiving surface lacking an anti-static bar, the nanofiber thread alignment can be low, with about 74% of nanofiber threads deposited in a low angle orientation. With an anti-static bar, under the same spinning conditions, the alignment can become about 92%. It may be appreciated that additional embodiments may include processes that incorporate the use of more than one anti-static bar.

Combined High Velocity and Alternating Ground Alignment

[0032] Enhanced alignment of polymer nanofibers produced during electrospinning has been achieved by various methods including, for example, high velocity fiber collection (for example, on a receiving surface, such as a mandrel, rotating at a high velocity) and fiber collection between sequentially placed electrodes on the rotating receiving surface. In one non-limiting embodiment, the receiving surface may be the rim surface of a metal spoked wheel. The rim surface of the wheel may be coated with a thin insulating layer, such as, for example, a thin layer of polystyrene or polystyrene film. In one non-limiting example, the sequential electrodes may be fabricated from conductive tape placed widthwise across the insulating material. At least one end of each tape electrode may contact one or more metal wheel spokes. The conductive tape may be composed of, for example, carbon or copper and may have a width of about 0.1 inches (0.25 cm) to about 2 inches (about 5 cm). In some embodiments, the conductive tape may be spaced in uniform intervals around the wheel rim. The intervals between the conductive tape and the insulating surface may create alternating layers of conductive and non-conductive surfaces. The metal spokes may be in electrical contact with the source of the electrospinning voltage providing the voltage difference between the polymer injection system and the receiving surface. The combination of a high speed rotational surface and a multiply grounded electrical surface may lead to enhanced fiber alignment.

[0033] FIG. 1 illustrates one example of a system for electrospinning a polymer nanofiber onto a mandrel to form a polymer network. A polymer injection device **115** may express the polymer solution in drops or in a continuous stream. An electrospun polymer nanofiber **120** may form during the transit of the liquid polymer from the injector **115** to the mandrel **105**. A voltage source may provide a high voltage to the injection device **115** with an appropriate ground to the mandrel **105**. The mandrel **105** may be mounted on a movable support **110**. In

one non-limiting embodiment, the high voltage ground may be in electrical communication with the support **110**. In another non-limiting embodiment, the high voltage ground may be in electrical communication with the mandrel **105**.

[0034] In one non-limiting example, the support **110** may cause the mandrel **105** to rotate either in a single direction during the electrospinning process, or in alternating directions. In an alternative non-limiting example, the support **110** may cause the mandrel **105** to translate along one or more linear axes, x, y and/or z during the electrospinning process, or in alternating directions. Such linear motions may permit the fiber **120** to attach to any portion along the length of the mandrel **105** (*viz.* in the z-direction). Alternatively, linear motions may cause the mandrel **105** to vary in its distance from the tip of the injection device **115** (x- and/or y- directions). It may be understood that the support **110** may move the mandrel **105** in a complex motion including both rotational and translational motions during the electrospinning process. It may further be appreciated that the speed of rotation and/or translation of the mandrel **105** during the electrospinning process may be uniform or non-uniform. It may also be appreciated that the mandrel **105** on the support **110** may be static and that the injection device **115** may rotate and/or translate with respect to the static mandrel.

[0035] As illustrated in FIG. 1, the electrospun fiber **120** may be wound about the mandrel **105** in a manner similar to that used to wind spun thread on a bobbin. The fiber **120** may be wound in any number of controlled configurations about the mandrel **105** based, at least in part, on one or more factors including the rate of polymer solution injection by the injection device **115**, the voltage potential between the injection device and the mandrel, and the rotational and/or translation speed of the support **110**. The mandrel **105** may have any shape appropriate to the type of luminal structure intended for manufacture. In one non-limiting example, the mandrel **105** may have a simple tubular shape, for example, for a vascular support structure. In another non-limiting example, the mandrel **105** may be composed of a structure having a single tubular end, and a bifurcated tubular end. It may be apparent that such a shape may be used to fabricate a polymer network appropriate to replace a trachea and attendant bronchi. In one non-limiting example, the mandrel **105** may be composed of metal. In another non-limiting example, the mandrel **105** may be coated with a non-stick material, such as, for example, aluminum foil or polytetrafluoroethylene, to permit easy removal of the polymer network from the mandrel. In still another non-limiting

embodiment, the mandrel **105** may have a collapsible construction, so that the mandrel may be removed from the polymer network by collapsing the mandrel within the polymer network, thereby freeing the polymer network from the mandrel surface. In yet another non-limiting embodiment, the mandrel **105**, having a completed polymer network wrapped around it, may be sprayed with a solvent, such as an alcohol, to loosen the polymer network from the mandrel, thereby permitting the polymer network to be removed from the mandrel, thereby forming the biocompatible textile. A mandrel **105** having a more complex shape may be fabricated from a number of reversibly attachable components. A polymer network fabricated on such a mandrel **105** may be removed from the mandrel surface by disassembling the mandrel.

[0036] As illustrated in FIG. 1, a rotating mandrel **105** may cause the fiber **120** to wrap around the mandrel outer surface forming a plurality of windings **125a,b**. The windings **125a,b** may be formed in regular, irregular, or a combination of regular and irregular patterns. In one embodiment, the windings **125a,b** may form a regular right-handed helix. In one embodiment, the windings **125a,b** may form a regular left-handed helix. In some embodiments, the windings **125a,b** may form a helix with about the same spacing between adjacent windings. In some embodiments, the windings **125a,b** may form a helix in which adjacent windings have different spacing between them. In some additional embodiments, the windings **125a,b** may not form a regular helix, and there may be overlap among some number of windings. In still another embodiment, the windings **125a,b** may be wound around the mandrel **105** in a random manner.

[0037] It may be apparent that the polymer network may be composed of a number of windings **125a,b**. The polymer network may be composed of a single layer of windings **125a,b**. In alternative embodiments, the polymer network may be composed of a number of layers of windings **125a,b**. In some embodiments, a number individual fibers **120** may be wound consecutively around the mandrel **105** to form one or more layers. In alternative embodiments, each layer may be composed of a number of windings **125a,b** of a single fiber **120**. In still alternative embodiments, a number of layers may be composed of a single fiber **120**, wound around the mandrel **105** in a succession of layers. It may be appreciated that a void or inter-fiber spacing **130** may be formed between adjacent windings, such as between winding **125a** and **125b**. Such inter-fiber spacings **130** may have a diameter of about 2 microns to about 5 microns. Alternatively, such inter-fiber spacings **130** may have a diameter

of about 30 micron to about 50 microns. It may be apparent that a textile may include a plurality of inter-fiber spacings **130** having a diameter of about 2 microns to about 50 microns. Non-limiting examples of such inter-fiber spacings may include about 2 μm , about 4 μm , about 6 μm , about 8 μm , about 10 μm , about 20 μm , about 30 μm , about 40 μm , about 50 μm , or ranges between any two of these values (including endpoints). In additional non-limiting examples, the inter-fiber spacings **130** may have a diameter less than or about equal to about 200 microns. The textile may alternatively be characterized by a mesh size. In some non-limiting embodiments, the textile may have a mesh size of about 20 inter-fiber spacings **130** per mm to about 500 inter-fiber spacings **130** per mm. Non-limiting examples of such mesh sizes may include about 20 spacings per mm, about 40 spacings per mm, about 60 spacings per mm, about 80 spacings per mm, about 100 spacings per mm, about 200 spacings per mm, about 300 spacings per mm, about 400 spacings per mm, about 500 spacings per mm, or ranges between any two of these values (including endpoints).

[0038] An alternative method for fabricating a biocompatible polymer textile may include surface treatments to further adjust the mesh size of the polymer network. In one embodiment, a surface treatment may include contacting particulate material **145a** with one or more of the electrospun fiber **120**, the mandrel **105**, or the polymer network disposed on the mandrel. In one non-limiting method, a particulate material **145b** may be contacted with the electrospun fiber **120** during the spinning step (**145b**) before the electrospun nanofiber contacts the mandrel **105**. In an alternative method, the particulate material **145c** may be contacted with a polymer network of electrospun fibers (**145c**) in contact with the mandrel **105**. The particulate material **145a** may be supplied from a particulate source **140** placed above or otherwise proximate to the electrospun fiber **120** or mandrel **105**. The particulate source **140** may include any device known in the art including, without limitation, a sieve or a shaker. The particulate source **140** may be mechanical in nature and may be controlled by an operator directly, a mechanical controller, an electrical controller, or any combination thereof.

[0039] The particulate material **145a** may be chosen from any material capable of being dissolved in a solvent that may not otherwise dissolve the electrospun fibers. In one non-limiting example, the solvent may be water, and the particulate material **145a** may include water soluble particulates. Non-limiting embodiments of such water-soluble particulates may include a water soluble salt, a water soluble sugar, a hydrogel, or combinations thereof. Non-

limiting examples of a water soluble salt may include NaCl, CaCl, CaSO₄, or KCl. Non-limiting examples of water soluble sugars may include sucrose, glucose, or lactose. The particulate material **145a** may have an average size of about 5 µm to about 300 µm. Non-limiting examples of the average size of such particulate material **145a** may include about 5 µm, about 10 µm, about 20 µm, about 40 µm, about 60 µm, about 80 µm, about 100 µm, about 150 µm, about 200 µm, about 250 µm, about 300 µm, or ranges between any two of these values (including endpoints).

[0040] Fabrication methods of multi-layer textiles may include additional steps. In some examples, groups of layers may be tack welded together either chemically or thermally. Alternatively, layers may be sintered together either through thermal or chemical means.

[0041] As disclosed above, a textile may be composed of a number of layers of windings **225**. Additional features may be added to the textile. In some non-limiting embodiments, the textile may include one or more curved support structures. Such structures may include rings or U-shaped supports disposed on the interior of the textile, exterior of the textile, or between successive layers of fiber windings **125a,b**. The curved supports may have any dimensions appropriate for their use. In some non-limiting examples, the supports may have a width of about 0.2 mm to about 3 mm. In some other non-limiting examples, the supports may have a thickness of about 1mm to about 5 mm. Such supports may be composed of one or more of the following: metals, ceramics, and polymers. Non-limiting examples of polymers used in such curved supports may include: a polyethylene terephthalate, a polyester, a polymethylmethacrylate, polyacrylonitrile, a silicone, a polyurethane, a polycarbonate, a polyether ketone ketone, a polyether ether ketone, a polyether imide, a polyamide, a polystyrene, a polyether sulfone, a polysulfone, a polycaprolactone (PCL), a polylactic acid (PLA), a polyglycolic acid (PGA), a polyglycerol sebacic, a polydiol citrate, a polyhydroxy butyrate, a polyether amide, a polydiaxanone, a chitosan, and combinations or derivatives thereof. Such support may further be composed of materials that may be non-resorbable or fully degradable. Such supports may be affixed on the mandrel **105** before the fiber **120** is wound about the mandrel surface to form the polymer network. Alternatively, such supports may be affixed on one pre-wound layer of fiber **120** of the polymer network before additional layers are wound on top of it. In yet another embodiment, such supports may be attached to the outer surface of the polymer network after the winding process is complete but before the polymer network is removed from the mandrel **105**. Alternatively, after the polymer network

has been removed from the mandrel **105**, thereby forming the biocompatible textile, additional supports may be added. Supports may be affixed on the polymer network or textile by any appropriate means, including, but not limited to, gluing, heat welding, and solvent welding. Additional supports may be formed of a mesh material over which the fibers **120** may be spun. Such a mesh support may be rigid, collapsible, and/or expandable.

[0042] The polymer network may receive any of a number of additional surface treatments while still in contact with the receiving surface. Alternatively, once the polymer network has been removed from the receiving surface, thereby forming the implantable biocompatible textile, such surface treatments may also be applied. Non-limiting examples of such surface treatments may include, without limitation, washing in a solvent, drying with a gas stream, sterilizing, sintering, or treating with a plasma discharge. Washing solvents may include water and alcohol. A drying gas stream may include air, nitrogen, or inert gas such as argon. A gas stream may include pressurized air or pressurized ionized air. Sterilization techniques may include gamma irradiation. Plasma discharge treatments may be performed in air or in another gas such as carbon tetrafluoride.

[0043] The disclosure above includes a number of embodiments and examples of polymer networks and biocompatible textiles fabricated by electrospinning a polymer to form windings about a mandrel. Such windings may be fabricated by rotating the mandrel about a longitudinal axis and contacting the electrospun polymer nanofiber with the mandrel. During the winding process, the mandrel additionally may be translated in any of a number of directions (in an x-direction, a y-direction, and a z-direction) with respect to the polymer injection device while simultaneously rotating about its longitudinal axis. Alternatively, the polymer networks or biocompatible textiles may be fabricated by translating the mandrel along a longitudinal axis to receive the electrospun polymer and rotating after a translation step has been accomplished. The resulting polymer network structure may not include windings (that is, a fiber deposited on the mandrel in a circular or curved path about the mandrel longitudinal axis) but rather may be composed of overlaid linear threads of fibers deposited on the mandrel surface along the longitudinal axis of the mandrel.

[0044] FIGS. 2A and 2B illustrate some examples of these geometries. As illustrated in FIG 2A, mandrel **205** on a support **210** may rotate about the longitudinal axis of the mandrel. The electrospun polymer may be contacted with the mandrel **205** while the mandrel rotates, thereby producing windings **225a**, **225b** about the longitudinal axis of the mandrel with a

spacing **230** therebetween. As illustrated in FIG. 2B, the mandrel **205** on the support **210** may be linearly translated while the polymer nanofiber contacts the mandrel surface. As a result, the electrospun nanofibers may form one or more textile threads **227a,b** having a primarily longitudinal orientation along the mandrel longitudinal axis. These textile threads **227a,b** may also be characterized by an inter-fiber spacing **230**. It may be appreciated that polymer networks or biocompatible textiles having a variety of fiber and/or winding orientations and spaces may be fabricated based on the direction and orientation of mandrel motion with respect to the polymer injector.

[0045] It may be understood that in the above disclosure, the use of a mandrel as a polymer receiving surface is not considered limiting. Other types of surfaces, including planar surfaces, circular surfaces, and irregular surfaces, may equally be used as receiving surfaces for the polymer electrospun fibers. Rotational and translations motions of such alternative receiving surfaces may result in any type of orientation of polymer nanofiber threads on or about the receiving surface. Thus, such polymer nanofiber threads may form, without limitation, windings, linear alignments, star-shaped alignments, or random alignments.

Biocompatibility

[0046] In certain instances, textiles can be manufactured that lack openings between the fibers, and may be considered “meshless” textiles. In such “meshless” textiles, the fibers may be too big to allow openings between neighboring fibers. Such fibers in “meshless” textiles may almost entirely overlap each other, thereby creating an effectively continuous textile surface. Pores, including, without limitation, pockets, spaces, voids, and holes, may be introduced into such “meshless” textiles. Those having skill in the art may recognize that, as one non-limiting example, methods capable of incorporating pores into a polymer block may also be used to introduce pores into “meshless” textiles. An artisan having average skill in the art may recognize that techniques used for introducing pores into a construct fabricated from a polymer may include, without limitation, solution casting, emulsion casting, polymer blending, and phase transition techniques.

[0047] Implants and methods that lead to patient death, or fail to delay, prevent, or mitigate morbidity and mortality, are not within the meaning of the term “biocompatible”. As such, in some embodiments, ineffective, toxic, or deadly compositions are expressly

disclaimed herein as they do not meet the necessary requirement of being biocompatible. In some embodiments, non-biocompatible compositions that are specifically disclaimed are: molded nanocomposites, molded polylactic acid (PLA), molded polyglycolic acid (PGA), molded polycaprolactone (PCL), polycaprolactone/polycarbonate (80:20%) polyhedral oligomeric silsesquioxane; polyhedral oligomer silsesquioxane nanocages; molded protein materials, molded collagen; molded fibrin, molded polysaccharides molded chitosan, molded glycosaminoglycans (GAGs); molded hyaluronic acid, a set nanocomposite material composed of polyhedral oligomeric silsesquioxane (POSS) covalently bonded to poly(carbonate-urea)urethane (PCU) to form a nanocomposite "POSS-PCU" polymer; a POSS-PCU fluid; coagulated POSS-PCU fluid; a POSS-PCU polymer fluid comprising salt crystals; a coagulated POSS-PCU polymer wherein the salt crystals are dissolved after coagulation to form pores; a coagulated POSS-PCU polymer wherein the salt crystals are a sodium salt, a lithium salt, a potassium salt, carbonate or bicarbonate salt, calcium carbonate, cobalt(II) carbonate, copper(II) carbonate, lanthanum carbonate, lead carbonate, lithium carbonate, magnesium carbonate, manganese(II) carbonate, nickel(II) carbonate, potassium carbonate or sodium carbonate; a POSS-PCU polymer wherein the average pore diameter may is about 20-100 microns; a molded polymer wherein the average pore diameter is about 20-100 microns, from about 1 nm to about 500 microns, an average diameter of about 10 nm to about 1 micron, about 1 to about 10 microns, about 10 to about 100 microns, about 10 to about 50 microns, about 50 to about 100 microns, about 100 to about 200 microns, about 200 to about 500 microns, and about 50-100 microns; and a polymer fluid containing 50% sodium bicarbonate having an average crystal size of about 40 microns.

Surgical procedures

[0048] While the prior disclosed composition of non-textile implants are not within the scope of the disclosure, certain other methods including surgical methods can be easily adapted for use with the disclosed textile implants. For example, a subject may be evaluated using one or more imaging techniques to identify the location and extent of damaged tissue that needs to be removed. In some non-limiting examples, the disclosed textiles may be seeded on both external and luminal surfaces with compatible cells that retain at least some ability to differentiate. In some embodiments, the cells may be autologous cells (e.g., mononuclear cells) that may be isolated from the patient (e.g., from the patient bone marrow) or a compatible donor. The seeding process may take place in a bioreactor (e.g., a rotating

bioreactor) for a few days prior to surgery. Just prior to surgery, additional cells may be added to the luminal surface of a synthetic tissue composed of a biocompatible textile. In some embodiments, these cells may be epithelial cells, which may be isolated from the patient's airway if the tissue is an airway tissue. Additionally, one or more growth factors may be added to the synthetic tissue immediately prior to surgery. The biocompatible textile incorporating such cells and/or additional chemical factors may then be transplanted into the patient to replace the damaged tissue that has been removed. The patient may be monitored post-surgically for signs of rejection or of a poorly functional airway transplant. It should be appreciated that the addition of cells and/or chemical factors to the biocompatible textile may not be required for every transplant surgery. Any one or more of these procedures may be useful alone or in combination to assist in the preparation and/or transplantation of a synthetic organ or tissue.

[0049] In certain embodiments, the biocompatible textiles disclosed herein are used as a tracheal implant. The natural trachea is a cartilaginous and membranous tube that extends from the lower part of the larynx (at the level of the sixth cervical vertebra) to the upper border of the fifth thoracic vertebra, where it branches to form the two bronchi. The trachea has the shape of a cylinder that is flattened at the back (posterior). The front (anterior) is convex. Without intending to be bound, a typical adult human trachea is at least about 10 cm long, and about 2-2.5 cm wide. However, it is generally larger in males and smaller in females. Sometimes, because of disease or trauma, a patient would benefit from having support or replacement of their airway or portion thereof (e.g., a trachea or portion thereof, a bronchus or portion thereof, or a combination thereof) with a biocompatible textile.

[0050] Any airway implant, whether comprising molded implants or textile implants, may be shaped or formed to represent the region or regions of the airway that is being replaced. In some embodiments, the airway implant may be roughly cylindrical, thereby forming an air flow conduit after implantation. Alternatively, the air flow conduit can have the natural shape of an airway region. For example, in cross-section, the conduit may have a D shape with a convex anterior (e.g., U-shaped) and a relatively straight posterior. The length of the conduit can be designed to effectively match (or be slightly longer than) the length of the airway region being replaced. The air flow conduit can be modeled on the portion of the patient's tissue that is to be replaced by the implant. Accordingly, the dimensions and shape of the implant can be designed to match those of the airway region being replaced. It should

be appreciated that, depending on the region that is being replaced, the overall shape of the conduit may be a straight conduit, a Y-shaped bifurcated conduit, or an L-shaped conduit.

[0051] As to care of a patient after implantation, certain biological functions may be monitored. For example, after implantation of a synthetic or natural trachea, patient follow-up may include, but is not limited to, endoscopic evaluation (flexible and/or rigid bronchoscopy) of the transplanted airway every day for the first week, every other day for the second week, once a month for the first six months thereafter, and every 6 months for the first 5 years thereafter. Additional patient follow-up may include an evaluation of the blood count, including white blood cell differentials, every second day for the first two weeks, evaluation of the hematopoietic stem cells, immunogenic evaluations (for example, a blood sample may be taken to study histocompatibility of the implant by evaluating the antibodies after 3 days, 7 days, 30 days, 3 months, 6 months, and 12 months after the transplant,), and computerized tomography of the neck and chest. Longer term patient follow-up for a transplanted airway can be performed at month 1, month 3, and month 6 of the follow-up, and every 6 months thereafter for the first 5 years. Additional oncological follow-up will be life-long and may include the standard evaluations for such medical condition. In certain embodiments, a biocompatible textile implant may be retained within the patient for 1 day, 3 days, 5 days, 7 days, 2 weeks, 3 weeks, or even a month or longer after implantation. Thus, such textiles can be retained in the patient for at least these lengths of time commensurate with biocompatibility of the implant as disclosed herein. In certain embodiments, a biocompatible textile implant is retained in a patient for 6 month, a year, a term of years, or even as long as the lifetime of the patient.

[0052] Although disclosed above are examples of the use of a biocompatible textile to replace tracheae or laryngeal structures, it may be appreciated that other biological structures, tissues, and organs having a luminal structure may also be replaced by biocompatible textile devices. Some non-limiting examples of such luminal structures may include a trachea, a trachea and at least a portion of at least one bronchus, a trachea and at least a portion of a larynx, a larynx, an esophagus, a large intestine, a small intestine, an upper bowel, a lower bowel, a vascular structure, and portions thereof.

[0053] In order to illustrate the various features disclosed above, the following non-limiting examples are provided.

EXAMPLES

[0054] Example 1: Method of Preparing a Biocompatible Textile

[0055] In preparing an exemplary textile, a polymer nanofiber precursor solution was prepared by dissolving 2-30 wt% polyethylene terephthalate (PET) in a mixture of 1,1,1,3,3,3-hexafluoroisopropanol and trifluoroacetic acid, and the solution was heated to 60°C followed by continuous stirring to dissolve the PET. The solution was cooled to room temperature and the solution placed in a syringe with a blunt tip needle. The nanofibers were formed by electrospinning using a high voltage DC power supply set to 1kV- 40kV positive or negative polarity, a 5-30 cm tip-to-substrate distance, and a 1 μ l/hr to about 100 ml/hr flow rate from the syringe. It is possible to use a needle array of up to 1,000's of needles to increase output. An approximately 0.2 -3.0 mm thickness of randomly oriented and/or highly-aligned fibers were deposited onto a receiving surface. Polymer rings were introduced onto the receiving surface and over the previously spun fibers, and an additional approximately 0.2-3.0 mm of fiber was added over the surface (including the additional polymer rings) while the form was rotated. The textile was placed in a vacuum overnight to ensure removal of residual solvent (typically less than 10 ppm) and treated using a radio frequency gas plasma for 1 minute to make the fibers more hydrophilic and promote cell attachment.

[0056] Example 2: A Biocompatible Textile Fabricated with Soluble Particulate Materials

[0057] FIGS. 3A and 3B depict two micrographs of biocompatible textiles, one formed without the addition of a soluble particulate material (FIG. 3A) and one formed with the addition of the soluble particulate material (FIG. 3B). The textiles were formed from a solution of polydioxane dissolved in hexafluoroisopropanol at a concentration of about 13 wt%. Polymer fibers having a fiber diameter of about 7 μ m were electrospun onto a mandrel. FIG 3A depicts the textile created from the polydioxane electrospun alone onto the mandrel and demonstrates a porosity of about 60% (in which porosity may be defined as the fraction of void space in a material). It may be observed that the porosity appears inconsistent across the area depicted in FIG 3A. A low porosity scaffold may be beneficial in applications where cellular infiltration is to be avoided or to decrease water permeability. However, a low porosity scaffold may be a disadvantage or a flaw in applications in which cellular infiltration in the scaffold may be desired. It may be appreciated that fibers bonded together as depicted

in FIG 3A may have mechanical properties that differ from those of a mesh scaffold lacking such bonding between fibers.

[0058] FIG 3B illustrates a micrograph of a textile formed from the same polymer solution and solvent, but which further included small particulates of NaCl added to the fiber during winding, to form a polymer network including salt. The salt particles had an average size of about 50 μm . To remove the salt from the polymer network, the network was submerged in three successive changes of water under gentle agitation using a stir bar for about 24 hrs. It may be observed in FIG. 3B that the textile mesh is more regular, having an average porosity of about 90%. It may be appreciated that the addition of a soluble particulate material having a known size during the fabrication of the textile may produce a more homogeneous porosity and may also be a more reproducible process for fabricating the textiles. Reproducibility of textile properties may improve the utility of the textiles in that the textiles may be more readily fabricated to meet known specifications. In addition to improved reproducibility of the electrospinning process, the addition of soluble particulates can facilitate the customization of the mesh size for specific applications. In one non-limiting example, it may be necessary to increase the mesh size of the textile to accommodate the seeding or culturing of large clusters of cells presented to the textile as cell spheroids. Such spheroids may contain hundreds of cells and may be up to several hundred microns in diameter. The larger mesh size may allow these spheroids to fit into the scaffold without destroying the cell cluster.

[0059] While the present invention has been illustrated by the description of exemplary embodiments thereof, and while the embodiments have been described in certain detail, it is not the intention of the Applicants to restrict or in any way limit the scope of the appended claims to such detail. Additional advantages and modifications will readily appear to those skilled in the art. Therefore, the invention in its broader aspects is not limited to any of the specific details, representative devices and methods, and/or illustrative examples shown and described. Accordingly, departures may be made from such details without departing from the spirit or scope of the applicant's general inventive concept.

CLAIMS

What is claimed is:

1. A biocompatible textile comprising:

at least one electrospun fiber, comprising at least one polymer, disposed on a mandrel, wherein:

the electrospun fiber forms a plurality of windings on the mandrel,
each winding of the plurality of windings forms an opening with an adjacent winding, thereby forming a plurality of openings between a plurality of adjacent windings, and
the plurality of openings comprises a mesh size.
2. The biocompatible textile of claim 1, wherein the textile is bio-stable.
3. The biocompatible textile of claim 1, wherein the textile is bio-absorbable or bio-degradable.
4. The biocompatible textile of claim 1, wherein the at least one polymer comprises polyethylene terephthalate, polyurethane, or any combination thereof.
5. The biocompatible textile of claim 4, wherein the at least one polymer comprises a combination of polyethylene terephthalate and polyurethane in a weight percent ratio of about 10% to about 75%.
6. The biocompatible textile of claim 1, wherein the the electrospun fiber is selected from one or more of electrospun polyethylene terephthalate, electrospun polyester, electrospun polymethylmethacrylate, electrospun polyacrylonitrile, electrospun silicone, electrospun polyurethane, electrospun polycarbonate, electrospun polyether ketone ketone, electrospun polyether ether ketone, electrospun polyether imide, electrospun polyamide, electrospun polystyrene, electrospun polyether sulfone, electrospun polysulfone, electrospun polycaprolactone (PCL), electrospun polylactic acid (PLA), electrospun polyglycolic acid (PGA), electrospun polyglycerol sebacic, electrospun polydiol citrate, electrospun polyhydroxy butyrate, electrospun polyether amide, electrospun polydioxanone, electrospun chitosan, and combinations or derivatives thereof.

7. The biocompatible textile of claim 1, wherein the at least one electrospun fiber comprises a plurality of electrospun fibers.
8. The biocompatible textile of claim 1, wherein the at least one electrospun fiber comprises an at least one surface-treated electrospun fiber.
9. The biocompatible textile of claim 8, wherein the at least one surface-treated electrospun fiber comprises an at least one electrospun fiber comprising a plurality of particles in physical communication with at least a portion of the surface of the electrospun fiber.
10. The biocompatible textile of claim 9, wherein the plurality of particles has an average particle size of about 5 μm to about 300 μm .
11. The biocompatible textile of claim 9, wherein the plurality of particles is water soluble.
12. The biocompatible textile of claim 9, wherein the plurality of particles comprises a salt, a sugar, a hydrogel material, or any combination thereof.
13. The biocompatible textile of claim 1, wherein the plurality of windings forms a plurality of circumferential layers.
14. The biocompatible textile of claim 13, wherein at least two of the plurality of circumferential layers have at least one point of mutual attachment defined by a tack weld.
15. The biocompatible textile of claim 13, wherein at least one of the plurality of circumferential layers comprises sintered windings of the at least one electrospun fiber.
16. The biocompatible textile of claim 13, wherein at least one of the plurality of circumferential layers is in physical contact with a plurality of water soluble particles.

17. The biocompatible textile of claim 13, wherein at least one of the plurality of circumferential layers has a mesh size determined by a spacing of about 2 micrometers to about 50 micrometers between adjacent windings of the at least one electrospun fiber.
18. The biocompatible textile of claim 13, further comprising at least one curved polymer support in mechanical communication with at least one of the plurality of circumferential layers.
19. The biocompatible textile of claim 18, wherein the at least one curved polymer support is a U-shaped support.
20. The biocompatible textile of claim 18, wherein the at least one curved polymer support comprises one or more of a polyethylene terephthalate, a polyester, a polymethylmethacrylate, polyacrylonitrile, a silicone, a polyurethane, a polycarbonate, a polyether ketone ketone, a polyether ether ketone, a polyether imide, a polyamide, a polystyrene, a polyether sulfone, a polysulfone, a polycaprolactone (PCL), a polylactic acid (PLA), a polyglycolic acid (PGA), a polyglycerol sebacic, a polydiol citrate, a polyhydroxy butyrate, a polyether amide, a polydiaxanone, a chitosan, and combinations or derivatives thereof.
21. The biocompatible textile of claim 18, wherein the at least one curved polymer support has a width of about 1mm to about 5mm.
22. The biocompatible textile of claim 18, wherein the at least one curved polymer support has a thickness of about 0.2mm to about 3mm.
23. The biocompatible textile of claim 18, wherein the at least one curved polymer support is in mechanical communication with an outer-most circumferential layer or an inner-most circumferential layer of at least one of the plurality of circumferential layers.
24. The biocompatible textile of claim 18, wherein the at least one curved polymer support is disposed between a first circumferential layer of the plurality of circumferential layers and a second circumferential layer of the plurality of circumferential layers.

25. The biocompatible textile of claim 18, further comprising at least one melted joint in mechanical communication with the at least one curved polymer support and with the at least one of the plurality of circumferential layers.
26. The biocompatible textile of claim 18, further comprising at least one glue joint in mechanical communication with the at least one curved polymer support and with the at least one of the plurality of circumferential layers.
27. The biocompatible textile of claim 26, wherein the at least one glue joint is one or more of a silicon adhesive joint and a solubilized polyurethane joint.
28. The biocompatible textile of claim 1, wherein at least one surface of the biocompatible textile comprises windings of the at least one electrospun fiber treated with a surface treatment.
29. The biocompatible textile of claim 1, wherein at least one surface of the biocompatible textile comprises windings of the at least one electrospun fiber exposed to a jet of pressurized air, a jet of pressurized ionized air, gamma radiation, and a solvent.
30. The biocompatible textile of claim 1, wherein at least one surface of the biocompatible textile comprises windings of the at least one electrospun fiber exposed to one or more of water and an alcohol.
31. The biocompatible textile of claim 1, wherein the biocompatible textile comprises windings of the at least one electrospun fiber sonicated in water, alcohol, or a combination thereof.
32. The biocompatible textile of claim 1, wherein at least one surface of the biocompatible textile comprises windings of the at least one electrospun fiber exposed to a gas plasma discharge.
33. The biocompatible textile of claim 32, wherein the gas is one or more of air and carbon tetrafluoride.
34. The biocompatible textile of claim 1, wherein the mandrel has a cylindrical shape.

35. The biocompatible textile of claim 1, wherein the mandrel has a biological organ-shape.
36. The biocompatible textile of claim 1, wherein the mandrel has a shape determined by a computer model.
37. The biocompatible textile of claim 1, wherein the mandrel is based on a biological organ of a patient.
38. The biocompatible textile of claim 1, wherein the mandrel is a collapsible mandrel.
39. The biocompatible textile of claim 1, wherein the mandrel has a non-stick surface comprising a polytetrafluoroethylene, a stainless steel, an aluminum, or combination thereof.
40. The biocompatible textile of claim 1, wherein the textile is not selected from the group consisting of molded nanocomposites, molded polylactic acid (PLA), molded polyglycolic acid (PGA), molded polycaprolactone (PCL), polycaprolactone/polycarbonate (80:20%) polyhedral oligomeric silsesquioxane; polyhedral oligomer silsesquioxane nanocages; molded protein materials, molded collagen; molded fibrin, molded polysaccharides molded chitosan, molded glycosaminoglycans (GAGs); molded hyaluronic acid, a set POSS-PCU nanocomposite material wherein polyhedral oligomeric silsesquioxane (POSS) is covalently bonded to poly(carbonate-urea)urethane (PCU) to form a nanocomposite "POSS-PCU" polymer; a POSS-PCU fluid; coagulated POSS-PCU fluid; a POSS-PCU polymer fluid comprising salt crystals; a coagulated POSS-PCU polymer wherein the salt crystals are dissolved after coagulation to form pores; a coagulated POSS-PCU polymer wherein the salt crystals are a sodium salt, a lithium salt, a potassium salt, carbonate or bicarbonate salt, calcium carbonate, cobalt(II) carbonate, copper(II) carbonate, lanthanum carbonate, lead carbonate, lithium carbonate, magnesium carbonate, manganese(II) carbonate, nickel(II) carbonate, potassium carbonate or sodium carbonate; a POSS-PCU polymer wherein the average pore diameter may be about 20-100 microns; a molded polymer wherein the average pore diameter is about 20-100 microns, from about 1 nm to about 500 microns, an average diameter of about 10 nm to about 1 micron, about 1 to about 10 microns, about 10 to about 100 microns, about 10 to about 50 microns, about 50 to about 100 microns, about 100 to about 200 microns, about 200 to about 500 microns, and about 50-100 microns; and a polymer fluid containing 50% sodium bicarbonate having an average crystal size of about 40 microns.

41. A biocompatible textile comprising:

an at least one electrospun fiber, comprising at least one polymer, disposed longitudinally along a linear axis of a mandrel, thereby forming a plurality of textile threads, wherein:

the at least one electrospun fiber forms openings between adjacent linearly deposited textile threads of a mesh size; and

the plurality of openings comprises a mesh size.

42. A method for fabricating a biocompatible textile comprising:

electrospinning a biocompatible polymer into an electrospun fiber;

contacting the electrospun fiber with a particulate material having a solubility in a solvent;

contacting the electrospun fiber with a receiving surface, thereby forming a polymer network thereon comprising a plurality of electrospun fiber threads and a plurality of spaces between adjacent electrospun fiber threads;

removing the polymer network from the receiving surface, thereby forming a biocompatible textile; and

contacting the biocompatible textile with the solvent thereby removing the particulate material,

wherein the plurality of openings comprises a mesh size.

43. The method of claim 42, wherein the solvent is water.

44. The method of claim 42, wherein the particulate material is a salt, a sugar, a hydrogel, or any combination thereof.

45. A replacement for an animal tissue comprising:

a biocompatible textile comprising:

at least one electrospun fiber, comprising at least one polymer, disposed on a mandrel, wherein:

the electrospun fiber forms a plurality of windings on the mandrel,

each winding of the plurality of windings forms an opening with an adjacent winding, thereby forming a plurality of openings between a plurality of adjacent windings, and

the plurality of openings comprises a mesh size,

wherein:

the mandrel has a shape of the animal tissue or part thereof, and

at least one surface of the biocompatible textile comprises windings of the at least one electrospun fiber treated with a surface treatment process.

46. The replacement for an animal tissue of claim 45, wherein the animal is a human.

47. The replacement for an animal tissue of claim 45, wherein the organ is one or more of a trachea, a trachea and at least a portion of at least one bronchus, a trachea and at least a portion of a larynx, a larynx, an esophagus, a large intestine, a small intestine, an upper bowel, a lower bowel, a vascular structure, and portions thereof.




FIG. 1

2/3




FIG. 2A




FIG. 2B




FIG. 3B




FIG. 3A

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US14/30700

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - D04H 1/74; D01D 5/06; A61F 2/02; B29C 53/56, 53/62, 53/72 (2014.01)

USPC - 156/173, 167, 169, 175, 273.1; 264/465, 413; 623/1.54, 11.11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): D04H 1/00; 1/74; D01D 5/00, 5/06; A61F 2/02; B29C 53/56, 53/62, 53/72 (2014.01)

USPC: 156/173, 167, 169, 175, 273.1; 264/465, 413; 623/1.54, 11.11

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MicroPatent (US-G, US-A, EP-A, EP-B, WO, JP-bib, DE-C,B, DE-A, DE-T, DE-U, GB-A, FR-A); ProQuest; IP.com; Google/Google Scholar; Key Words: bio*compatible, bio*degradable, bio*stable, textile*, fabric*, polymer*, mandrel, substrate, preform*, fiber*, fibre*, electrospin*, electrospun, wind*, wound, mesh, opening*, pore*, porosity, size, layer*, polyethylene terephthalate, polyurethane*, support

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 4,738,740 A (PINCHUK, L et al.) 19 April 1988; abstract; column 4, lines 21-22; column 5, lines 32-40; column 6, lines 26-29; figure 3; claims 1-2, 9, 11	1, 3-4, 6-7, 13, 17, 40 ----- 2, 5, 8-12, 14-16, 18-39, 42-47
X -- Y	US 7,115,220 B2 (DUBSON, A et al.) 03 October 2006; abstract; column 3, lines 14-16; column 10, lines 60-63; column 12, lines 36-39; column 14, lines 26-28, 31-34	41 ----- 2, 39
Y	US 2006/0134157 A1 (LEHMAN, R et al.) 22 June 2006; abstract; paragraph [0032]; claims 1, 6	5
Y	WO 2005/012606 A2 (KAPLAN, DL et al.) 10 February 2005; paragraphs [0014], [0047], [0071], [0086], [0096]; claims 21, 29	8-12, 16, 28-30, 42-47
Y	US 8,157,722 B2 (ARNAL, KR et al.) 17 April 2012; column 12, lines 53-57	14
Y	US 5,628,788 A (PINCHUK, L) 13 May 1997; column 5, lines 9-14	15
Y	US 2007/0191956 A1 (PREWETT, A et al.) 16 August 2007; paragraphs [0009], [0034], [0036]	18-27
Y	US 2012/0068384 A1 (PHANEUF, MD et al.) 22 March 2012; paragraph [0116]	31
Y	US 2006/0154063 A1 (FUJIHARA, K et al.) 13 July 2006; paragraph [0110]	32-33



Further documents are listed in the continuation of Box C.



*

Special categories of cited documents:

"A"

document defining the general state of the art which is not considered to be of particular relevance

"E"

earlier application or patent but published on or after the international filing date

"L"

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O"

document referring to an oral disclosure, use, exhibition or other means

"P"

document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

07 July 2014 (07.07.2014)

Date of mailing of the international search report

27 AUG 2014

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US14/30700

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/15754 A1 (BOWLIN, G et al.) 08 March 2001; claims 13-14	34-35, 37, 45-47
Y	EP 0416846 A2 (CURTIS, JM) 13 March 1991; column 4, lines 56-59	36
Y	US 6,143,022 A (SHULL, SL et al.) 07 November 2000; column 12, lines 38-39	38
Y	US 2007/0142907 A1 (MOADDEB, S et al.) 21 June 2007; paragraphs [0109], [0113], [0118]; claims 1, 4	19, 21, 25-27
Y	US 7,220,281 B2 (LAMBRECHT, GH et al.) 22 May 2007; claim 14	22